Becoming a strong regional player and the first partnering choice
Expanding the product portfolio will strenghten the growth potential.
Grow organically in selected new markets to become a strong regional player with stable, geographically diversified revenues by:
Maintain the Company’s position as a leading Bulgarian pharmaceutical manufacturer with high quality affordable products and improve existing products.
5 Marketing Authorization was obtained for a new medicinal product - Solifenax 5 mg film-coated tablet (Bulgaria) ), Ambrolitin 30 mg/5 ml syrop (Bulgaria, Latvia, Estonia), Ketoprofen 100 mg/ 2 ml solution for injection (Bulgaria), Sofazolon 40mg powder and solvent for solution for injection (Bulgaria), Dexketoprofen 50mg/2ml solution for injection (Latvia, Lithuania, Estonia).
Further consolidate and integrate the Group to optimize its cost structure, control entirely the production chain and benefit from potential synergies.